Apellis Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-6.132; its P/E ratio is -10.13; Apellis Pharmaceuticals is scheduled to report earnings on May 3, 2023, and the estimated EPS forecast is $-1.47. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	$ 22.66M	$ 22.06M	$ 16.32M	$ 14.38M	$ 60.29M
Gross Profit	$ 19.74M	$ 20.68M	$ 16.24M	$ 13.13M	$ 55.24M
EBIT	$ -159.72M	$ -182.92M	$ -147.04M	$ -129.19M	$ -144.56M
EBITDA	$ -159.30M	$ -182.56M	$ -146.70M	$ -128.83M	$ -144.19M
Net Income Common Stockholders	$ -165.99M	$ -191.27M	$ -155.98M	$ -138.94M	$ -147.93M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 551.80M	$ 708.55M	$ 852.80M	$ 965.30M	$ 700.55M
Total Assets	$ 760.22M	$ 872.89M	$ 1.00B	$ 1.15B	$ 881.76M
Total Debt	$ 112.71M	$ 113.37M	$ 211.30M	$ 210.42M	$ 210.22M
Net Debt	$ -439.09M	$ -595.18M	$ -641.50M	$ -754.88M	$ -490.33M
Total Liabilities	$ 590.35M	$ 565.48M	$ 668.08M	$ 683.62M	$ 683.10M
Stockholders Equity	$ 169.87M	$ 307.42M	$ 334.42M	$ 462.24M	$ 198.66M
Cash Flow	-
Free Cash Flow	$ -141.59M	$ -154.61M	$ -107.42M	$ -111.65M	$ -112.52M
Operating Cash Flow	$ -140.74M	$ -154.42M	$ -107.02M	$ -111.56M	$ -112.50M
Investing Cash Flow	$ 124.13M	$ 124.78M	$ 82.93M	$ -271.95M	$ 84.98M
Financing Cash Flow	$ -15.95M	$ 9.64M	$ -4.74M	$ 376.70M	$ 383.96M

Currency in USD

Apellis Pharmaceuticals Earnings and Revenue History

Income Statement >

Apellis Pharmaceuticals Debt to Assets

Balance Sheet >

Apellis Pharmaceuticals Cash Flow

Cash Flow >

Apellis Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing